United Therapeutics Corp (UTHR)

92.47 +0.59  +0.64% NASDAQ Jan 22, 17:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/27/2020 09:00 EST Misc United Therapeutics Corp Fourth Quarter Earnings Conference Call in 2019
02/27/2020 Earnings United Therapeutics Corp Fourth Quarter Earnings in 2019 Release
10/30/2019 09:00 EDT Misc United Therapeutics Corp Third Quarter Earnings Conference Call for 2019
10/30/2019 Earnings United Therapeutics Corp Third Quarter Earnings in 2019 Release
07/31/2019 09:00 EDT Misc United Therapeutics Corp Second Quarter Earnings Conference Call in 2019
07/31/2019 Earnings United Therapeutics Corp Second Quarter Earnings in 2019 Release
06/26/2019 08:00 EDT Misc United Therapeutics Corp Annual General Meeting in 2018
05/01/2019 09:00 EDT Misc United Therapeutics Corp First Quarter Earnings Conference Call in 2019
05/01/2019 Earnings United Therapeutics Corp First Quarter Earnings in 2019 Release
02/27/2019 09:00 EST Misc United Therapeutics Corp Fourth Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.unither.com
  • Investor Relations URL: http://ir.unither.com/
  • HQ State/Province: Maryland
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Feb. 27, 2020
  • Last Earnings Release: Oct. 30, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for pulmonary arterial hypertension largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Nearly all of its sales are generated within the United States. United also markets a pediatric oncology drug, but its focus largely remains in pulmonary hypertension.

Top Fund Holders

Symbol Name Weighting
DGQUX AmericaFirst Defensive Growth U 4.74%
SBIO ALPS Medical Breakthroughs ETF 3.67%
FBT First Trust NYSE Arca Biotech ETF 3.33%
RIVSX River Oak Discovery 2.80%
AMLCX AlphaMark Large Cap Growth 2.40%
BIP912 Brandes Global Small Cap Equity Cl D 2.09%
XBI SPDR® S&P Biotech ETF 1.79%
IMPLX ERShares US Large Cap Fund™ Inst 1.68%
BBH VanEck Vectors Biotech ETF 1.38%
FDMLX Fidelity® Series Intrinsic Opps 1.28%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.81%
PSC Principal US Small Cap Mlt Fac Ind ETF 0.72%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.